Eligibility
18+
All Sexes
What conditions do you have?
Select
Study Summary
This trial is testing whether apixaban is better than aspirin at preventing strokes or death in patients who have recently had a bleed in the brain and also have atrial fibrillation.
Eligible Conditions
- Cerebral Hemorrhage
- Atrial Fibrillation
Treatment Effectiveness
Effectiveness Progress
This is further along than 85% of similar trials
Study Objectives
1 Primary · 1 Secondary · Reporting Duration: Up to 3 years
Month 12
Modified Rankin Scale (mRS) score
Up to 3 years
Stroke or death
Trial Safety
Safety Progress
This is further along than 85% of similar trials
Trial Design
2 Treatment Groups
Apixaban
1 of 2
Aspirin
1 of 2
Active Control
Non-Treatment Group
700 Total Participants · 2 Treatment Groups
Primary Treatment: Apixaban · Has Placebo Group · Phase 3
Aspirin
Drug
PlaceboComparator Group · 1 Intervention: Aspirin · Intervention Types: DrugApixaban
Drug
ActiveComparator Group · 1 Intervention: Apixaban · Intervention Types: DrugTrial Logistics
Trial Timeline
Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: up to 3 years
Who is running the clinical trial?
Yale UniversityLead Sponsor
1,666 Previous Clinical Trials
21,074,090 Total Patients Enrolled
6 Trials studying Cerebral Hemorrhage
3,013 Patients Enrolled for Cerebral Hemorrhage
National Institute of Neurological Disorders and Stroke (NINDS)NIH
1,250 Previous Clinical Trials
451,653 Total Patients Enrolled
20 Trials studying Cerebral Hemorrhage
21,293 Patients Enrolled for Cerebral Hemorrhage
Kevin N Sheth, MDPrincipal InvestigatorYale School of Medicine
1 Previous Clinical Trials
88 Total Patients Enrolled
Hooman Kamel, MDPrincipal InvestigatorWeill Medical College of Cornell University
Eligibility Criteria
Age 18+ · All Participants · 7 Total Inclusion Criteria
Mark “yes” if the following statements are true for you:You are at least 18 years old.
You have atrial fibrillation or atrial flutter.
You have a CHA2DS2-VASc score ≥ 2.
You have signed and dated an informed consent form.
About The Reviewer
Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.
Popular Clinical Trials
Top Clinical Trials in Cities
Relevant Clinical Trials
Unbiased Results
We believe in providing patients with all the options.Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.Back to top
Conditions
Cancer Related
Treatments